LivaNova PLC (LIVN)
NASDAQ: LIVN · IEX Real-Time Price · USD
59.60
+0.22 (0.37%)
At close: May 24, 2024, 4:00 PM
60.76
+1.16 (1.95%)
After-hours: May 24, 2024, 4:41 PM EDT

Company Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.

The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments.

The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices.

The Advanced Circulatory Support segment develops, produces, and sells temporary life support products.

It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.

The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

LivaNova PLC
LivaNova logo
Country United Kingdom
Founded 1987
IPO Date Feb 10, 1993
Industry Medical Devices
Sector Healthcare
Employees 2,900
CEO Vladimir A. Makatsaria

Contact Details

Address:
20 Eastbourne Terrace
London, X0 W2 6LG
United Kingdom
Phone 4402033250662
Website livanova.com

Stock Details

Ticker Symbol LIVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001639691
CUSIP Number G5509L101
ISIN Number GB00BYMT0J19
Employer ID 98-1268150
SIC Code 3845

Key Executives

Name Position
Alex Shvartsburg Chief Financial Officer
Trui Hebbelinck Chief Human Resources Officer
Vladimir A. Makatsaria Chief Executive Officer and Director
Badri Amurthur Chief Technology Officer
Lindsey Little Senior Director of Investor Relations
Michael D. Hutchinson Senior Vice President, Chief Legal Officer and Company Secretary
Deanna Wilke Vice President of Corporate Communications
Matthew Joseph Dodds III Senior Vice President of Corporate Development and IT
Dr. Bryan D. Olin Ph.D. Senior Vice President and Head of Product Development - Neuromodulation
Ryan Miller President of Advanced Circulatory Support

Latest SEC Filings

Date Type Title
May 3, 2024 IRANNOTICE Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012
May 3, 2024 10-Q Quarterly Report
May 1, 2024 8-K Current Report
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 17, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 8, 2024 8-K Current Report
Mar 6, 2024 8-K Current Report
Mar 4, 2024 8-K Current Report